Healthy adults
Conditions
Interventions
Ingestion of test food (tablets that contain phycocyanin) for 9 weeks
Ingestion of placebo (tablets that don'
t contain phycocyanin) for 9 weeks
Sponsors
DRC Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy male and female aged between 30 and 60 at the time of informed consent 2. Subjects whose Fitzpatrick skin phototype is type II or type III 3. Subjects whose dorsal skin can be determined to have UV erythema 4. Subjects who were judged to have MED in the second, third, fourth, fifth of the six levels of UV radiation at the time of MED judgment before ingestion of the test product (Day 1) 5. Subjects who be able to visit the test site on all test days 6. Subjects who can provide written consent to participate in the study voluntarily
Exclusion criteria
Exclusion criteria: 1. Subjects who have symptoms of skin diseases on the evaluation site which may affect the test results 2. Subjects with photosensitivity disorder 3. Subjects who continuously take a functional food or quasi-medicine which has same or similar effect with active ingredient of test food 4. Subjects who got some cosmetic surgery, or hormone therapy which would affect the target skins, or plan to do so during the examination period 5. Subjects who have undergone any special skin care treatment within the past 4 weeks, or plan to do so during the examination period 6. Subjects who use pharmaceuticals and quasi-drugs effective in the treatment of UV-induced skin pigmentation and chloasma 7. Subjects who have risk for allergy related to test foods 8. Subjects who plan to have ultraviolet exposure within a month before the screening test 9. Shift workers 10. Subjects who are undergoing medical treatment or who requires medical or prophylactic treatment at the time of informed consent 11. Subjects who take medicine that affect light sensitivity of skin 12. Subjects taking anti-inflammatory medicine at least once a month, or who are planning to take them during the study period 13. Subjects who have a medical history for severe disease or abnormality in glucose or lipid metabolism, endocrine or nerve system, or for psychiatric disorder 14. Subjects who have a medical history or present illness of serious hepatopathy, kidney damage, heart disease, hematological and blood disease 15. Subjects who have a medical history of alcoholism or drug addiction 16. Subjects who are pregnant or lactating, or who intend to become pregnant 17. Subjects who were involved in another clinical studies within 4 weeks prior to the trial, or who will participate in another clinical studies 18. Subjects who have changed and/or started using functional foods and/or sunscreen on the target area within 4 weeks. 19. Subjects who are judged as unsuitable participant by the doctor for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Minimal erythema dose (MED) Evaluate before and 8 weeks after intake. | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin color (L*, a*, b*); Evaluate before, 8 weeks and 9 weeks after intake. photography of irradiated area; Evaluate before, 8 weeks and 9 weeks after intake. blood pentosidine; Evaluate before and 9 weeks after intake. | — |
Countries
Japan
Contacts
Public ContactKazumi Naganuma
DRC Co., Ltd. Product Testing Department
Outcome results
None listed